🎉 M&A multiples are live!
Check it out!

Cue Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cue Biopharma and similar public comparables like Vivoryon Therapeutics, Galapagos, and Benevolent AI.

Cue Biopharma Overview

About Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.


Founded

2014

HQ

United States of America
Employees

41

Financials

LTM Revenue $8.7M

Last FY EBITDA -$37.5M

EV

$45.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cue Biopharma Financials

Cue Biopharma has a last 12-month revenue (LTM) of $8.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Cue Biopharma achieved revenue of $9.3M and an EBITDA of -$37.5M.

Cue Biopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cue Biopharma valuation multiples based on analyst estimates

Cue Biopharma P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $8.7M XXX $9.3M XXX XXX XXX
Gross Profit $8.7M XXX n/a XXX XXX XXX
Gross Margin 100% XXX n/a XXX XXX XXX
EBITDA n/a XXX -$37.5M XXX XXX XXX
EBITDA Margin n/a XXX -404% XXX XXX XXX
EBIT -$40.3M XXX -$41.6M XXX XXX XXX
EBIT Margin -463% XXX -448% XXX XXX XXX
Net Profit -$39.7M XXX -$40.7M XXX XXX XXX
Net Margin -456% XXX -438% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cue Biopharma Stock Performance

As of June 23, 2025, Cue Biopharma's stock price is $1.

Cue Biopharma has current market cap of $51.8M, and EV of $45.8M.

See Cue Biopharma trading valuation data

Cue Biopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$45.8M $51.8M XXX XXX XXX XXX $-0.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Cue Biopharma Valuation Multiples

As of June 23, 2025, Cue Biopharma has market cap of $51.8M and EV of $45.8M.

Cue Biopharma's trades at 4.9x EV/Revenue multiple, and -1.2x EV/EBITDA.

Equity research analysts estimate Cue Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Cue Biopharma has a P/E ratio of -1.3x.

See valuation multiples for Cue Biopharma and 12K+ public comps

Cue Biopharma Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $51.8M XXX $51.8M XXX XXX XXX
EV (current) $45.8M XXX $45.8M XXX XXX XXX
EV/Revenue 5.3x XXX 4.9x XXX XXX XXX
EV/EBITDA n/a XXX -1.2x XXX XXX XXX
EV/EBIT -1.1x XXX -1.1x XXX XXX XXX
EV/Gross Profit 5.3x XXX n/a XXX XXX XXX
P/E -1.3x XXX -1.3x XXX XXX XXX
EV/FCF n/a XXX -1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cue Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Cue Biopharma Margins & Growth Rates

Cue Biopharma's last 12 month revenue growth is 3%

Cue Biopharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.2M for the same period.

Cue Biopharma's rule of 40 is -836% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cue Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Cue Biopharma and other 12K+ public comps

Cue Biopharma Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 3% XXX 4% XXX XXX XXX
EBITDA Margin n/a XXX -404% XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 -836% XXX -401% XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $0.2M XXX XXX XXX
Opex per Employee XXX XXX $1.2M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 391% XXX XXX XXX
Opex to Revenue XXX XXX 548% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cue Biopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cue Biopharma M&A and Investment Activity

Cue Biopharma acquired  XXX companies to date.

Last acquisition by Cue Biopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cue Biopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cue Biopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Cue Biopharma

When was Cue Biopharma founded? Cue Biopharma was founded in 2014.
Where is Cue Biopharma headquartered? Cue Biopharma is headquartered in United States of America.
How many employees does Cue Biopharma have? As of today, Cue Biopharma has 41 employees.
Who is the CEO of Cue Biopharma? Cue Biopharma's CEO is Mr. Daniel R. Passeri.
Is Cue Biopharma publicy listed? Yes, Cue Biopharma is a public company listed on NAS.
What is the stock symbol of Cue Biopharma? Cue Biopharma trades under CUE ticker.
When did Cue Biopharma go public? Cue Biopharma went public in 2018.
Who are competitors of Cue Biopharma? Similar companies to Cue Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Cue Biopharma? Cue Biopharma's current market cap is $51.8M
What is the current revenue of Cue Biopharma? Cue Biopharma's last 12 months revenue is $8.7M.
What is the current revenue growth of Cue Biopharma? Cue Biopharma revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of Cue Biopharma? Current revenue multiple of Cue Biopharma is 5.3x.
Is Cue Biopharma profitable? Yes, Cue Biopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.